(Q42166618)

17 October 2017

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol (English)

1 reference

glucocorticoid-induced osteoporosis

17 October 2017

0 references

1 reference

Seiji Takeda

1

1 reference

17 October 2017

Hidetoshi Kaneoka

series ordinal

2

1 reference

17 October 2017

Takao Saito

series ordinal

3

1 reference

17 October 2017

language of work or name

1 reference

22 April 2008

1 reference

17 October 2017

1 reference

17 October 2017

18

1 reference

17 October 2017

3

1 reference

17 October 2017

271-276

1 reference

The treatment of glucocorticoid-induced osteoporosis

17 October 2017

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

Management of corticosteroid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

Adverse effects of oral corticosteroids in relation to dose in patients with lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-008-0055-Y

10.3109/S10165-008-0055-Y

21 January 2018

Identifiers

DOI

1 reference

17 October 2017

1 reference